Adults want control of their private health data
AUSTIN, Texas — An overwhelming majority of respondents to a recent poll want to choose which companies and government agencies can view and use their health information.
An online survey of more than 2,000 adults conducted in November by the advocacy group Patient Privacy Rights and Zogby International — with a margin of error of plus or minus 2.2% — found that nearly all respondents favored personal control over health information, including information stored electronically. “No matter how you look at it, Americans want to control their own private health information,” Patient Privacy Rights founder Deborah Peel said. “We asked the question, ‘If you have health records in electronic systems, do you want to decide which companies and government agencies can see and use your sensitive data?’ Ninety-three percent said ‘Yes.’”
Nearly all respondents shared these sentiments; 97% said they thought doctors, hospitals, labs and health technology systems should not be allowed to share or sell health information without their consent, while 98% said insurance companies should not. Ninety-one percent of respondents said they wanted the ability to decide which individuals could see and use their information. “Americans overwhelmingly believe that they are the only people in the right position to make decisions about how their information can be used,” Peel said. “Researchers do not get a free pass.”
The results are significant considering the country’s move toward electronic health records and electronic prescribing, provisions for which were a prominent component of the American Recovery and Reinvestment Act of 2009. While supporters said the move to EHRs could save billions of dollars by reducing the risk of errors and eliminating waste, concerns about fraud and misuse of patients’ personal information have arisen as well.
Another poll, conducted online in February by Harris Interactive on behalf of Xerox — which provides a number of healthcare IT and documentation products and services — found that nearly half of the 2,180 adults surveyed were ready to give up paper medical records in favor of electronic ones and thought EHRs would lead to more efficient health care, despite many not knowing what to expect when the transition took place. A majority of respondents to the Harris poll still expressed concerns, including 79% who feared theft of records, 69% who were concerned about misuse of information and 68% who were afraid of lost or damaged records.
“Providers can ease this fear by discussing the security precautions taken to safeguard against data breaches,” Xerox VP healthcare providers John Jones said. “By arming Americans with information on EHR basics, we can prevent some of the influence of the media hype cycle around potential security risks.”
Sun seeks to acquire Caraco
DETROIT — An India-based drug maker is looking to acquire all outstanding shares of another generic drug manufacturer based in the United States.
Caraco said it received and will discuss the proposal from Sun Pharma, by which Sun would acquire all outstanding shares of common stock it doesn’t already own.
The $4.75-per-share cash transaction represents a 5% premium over the closing price of Caraco common stock on Dec. 2, Caraco said.
Genentech: Rituxan improved asymptomatic follicular lymphoma symptoms among patients in trial
SOUTH SAN FRANCISCO, Calif. — A biotech drug made by Roche subsidiary Genentech allowed patients with a blood cancer, who did not show symptoms, to delay starting on chemotherapy or radiotherapy, and decreased the risk of their disease worsening, according to results of a late-stage clinical trial.
Genentech said results of the trial of Rituxan (rituximab) showed that patients with asymptomatic follicular lymphoma who immediately received the drug fared better than those who took a “watchful waiting approach,” meaning they waited until the disease began showing symptoms and worsening. Compared with the “watchful waiting” approach, patients receiving Rituxan decreased the risk of needing additional therapy by 80% and decreased the risk of the disease worsening by 79%.
“These are the first phase-3 data to have shown that initial use of Rituxan monotherapy as induction followed by maintenance had an impact in patients with asymptomatic follicular lymphoma, a disease that is commonly treated only after symptoms appear,” Genentech EVP product development and chief medical officer Hal Barron said. “Early treatment interventions in prior studies in this population were not considered to provide meaningful clinical benefit.”